CRP and type 2 diabetes mellitus: SGLT2i intervention in patients with T2D led to improvements in inflammation biomarkers by decreasing the NLR (0.68 vs. 0.72; p < 0.001), PLR (115 vs. 122; p < 0.001) and C-reactive protein (3.07 mg/L vs. 4.37 mg/L; p < 0.001: Figure 2).